FDA Clears Updated AI-Powered Software for Chest CT Lung Assessment
The AI-enabled LungQ® 4 software reportedly offers enhanced segmentation of peripheral airways and estimates of chronic perfusion deficits based on analysis of chest CT scans.
Providing expanded capabilities in AI-powered lung assessment with chest computed tomography (CT) exams, the updated LungQ® 4 software has garnered 510(k) clearance from the Food and Drug Administration (FDA).
The peripheral airway segmentation available with the LungQ 4 software enable radiologists to see distal airways within peripheral regions of the lung that were previously inaccessible, according to Thirona, the manufacturer of the LungQ 4 software.
Thirona added that the PXT feature with the LungQ 4 software provides quantitative insights similar to what one would obtain with single-photon emission computed tomography (SPECT) and facilitates targeted treatment in lung volume reduction.
For patients who have had lung volume reduction, Thirona pointed out that the LungQ 4 software allows for post-op position monitoring of endobronchial implants.
“With LungQ 4, we’ve come a long way in translating our AI technology into trusted tools that actually work in everyday care, implemented in close collaboration with our partners across advanced clinical systems and solutions used by physicians around the world,” noted Eva van Rikxoort, PhD, the CEO of Thirona.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
